Progen gets in synth

By Dylan Bushell-Embling
Wednesday, 02 July, 2008

Brisbane biotech Progen Pharmaceuticals (ASX: PGL) has spun out its manufacturing business into a wholly-owned subsidiary.

The new subsidiary will be called PharmaSynth, and will be responsible for completing Progen's PI-88 manufacturing process.

It will also offer process development and manufacturing services to the biotechnology industry.

Progen's former director of manufacturing operations, Les Tillack, is the new company's CEO.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd